Bio-Plexus and TFX Medical in License, Development and Sales Agreement.VERNON, Conn.--(BW HealthWire)--Oct. 30, 1998--Bio-Plexus, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :BPLX), designer, developer, manufacturer, and marketer of safety medical needles and other products under the PUNCTUR-GUARD(R) name, today announced an exclusive License, Development and Sales Agreement for a PICC PICC Peripherally-inserted central catheter Critical care An IV catheter inserted in the superior vena cava for long-term infusion of bolus or continuous delivery of therapeutics or TPN–drugs, fluids, nutrients, chemotherapy. Cf Catheter. Introducer Catheter, with TFX Medical of Jaffrey, New Hampshire Jaffrey is a town in Cheshire County, New Hampshire, USA. The population was 5,476 at the 2000 census. History First granted in 1736 to soldiers from Rowley, Massachusetts returning from the war in Canada, the town was known as "Rowley-Canada. . TFX Medical is a division of Teleflex Incorporated (NYSE NYSE See: New York Stock Exchange :TFX) and is the industry's dominant supplier of PICC Introducers. "The License Agreement with Teleflex includes certain minimum annual volume requirements and ongoing royalties on the sale of PICC Introducer Catheters featuring Punctur-Guard technology," according to Bio-Plexus President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Richard L. Higgins. "This agreement exemplifies our strategy to develop a series of relationships which apply our core technology to products in a variety of hollow-bore needle markets," he continued. "When viewed in conjunction with the new California law mandating the use of safety needles, it is another strong indicator of the market's recognition of the importance of safety and the positive merits of the Punctur-Guard internal blunting technology," Higgins concluded. Bio-Plexus holds U.S. and international patents on safety medical devices marketed under the Punctur-Guard and Drop-It brand names. These devices are designed to reduce the incidence of accidental needlesticks among healthcare workers. In a Centers for Disease Control study, Punctur-Guard Blood Collection Needles were found to reduce the rate of accidental needlesticks by 76%, the highest rate of any device studied. Accidental needlesticks number more than 950,000 per year in the United States and can result in the transmission of deadly diseases including HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. and Hepatitis B and C. NOTE: THIS PRESS RELEASE MAY CONTAIN FORWARD-LOOKING STATEMENTS, WHICH ARE SUBJECT TO CHANGE. THE ACTUAL RESULTS MAY DIFFER MATERIALLY FROM THOSE DESCRIBED IN ANY FORWARD-LOOKING STATEMENT. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion